Meet Jacob Licht and VLP Therapeutics
VLP Therapeutics was established in 2013 with the mission to develop innovative medical treatments which can transform traditional vaccines and targeted antibody therapies to address global unmet medical needs. Its vision is to combat 21st century global public health problems through its revolutionary next generation i-αVLP technology platform. VLP is currently developing vaccines to treat cancer and infectious diseases such as Malaria and Dengue Fever.
VLP Therapeutics Announced Phase 1 SBIR Grant Award From National Cancer Institute. The grant will support development of novel Virus-Like Particle vaccine-based cancer immunotherapy. Read more here
Contact: Jacob Licht – Email: jlicht@vlptherapeutics.com